Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Share-based Compensation: 2010-2025

Historic Share-based Compensation for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Sep 2025 value amounting to $63.4 million.

  • Arrowhead Pharmaceuticals' Share-based Compensation fell 1.99% to $19.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $63.4 million, marking a year-over-year decrease of 14.33%. This contributed to the annual value of $63.4 million for FY2025, which is 14.33% down from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported Share-based Compensation of $63.4 million as of FY2025, which was down 14.33% from $74.0 million recorded in FY2024.
  • Arrowhead Pharmaceuticals' 5-year Share-based Compensation high stood at $120.9 million for FY2022, and its period low was $63.4 million during FY2025.
  • For the 3-year period, Arrowhead Pharmaceuticals' Share-based Compensation averaged around $71.8 million, with its median value being $74.0 million (2024).
  • Per our database at Business Quant, Arrowhead Pharmaceuticals' Share-based Compensation spiked by 76.74% in 2021 and then slumped by 35.37% in 2023.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Share-based Compensation (Yearly) stood at $76.7 million in 2021, then skyrocketed by 57.67% to $120.9 million in 2022, then slumped by 35.37% to $78.1 million in 2023, then fell by 5.33% to $74.0 million in 2024, then declined by 14.33% to $63.4 million in 2025.